

6 November 2017

ASX Limited  
Level 6, Exchange Centre  
20 Bridge Street  
Sydney NSW 2000

**NOXOPHARM LIMITED (“NOX”)  
Results of General Meeting (“EGM”) of Members – 6 November 2017**

We advise that:

A. A summary of valid and eligible proxies received for the above meeting was as follows:

Resolution No and Type	Resolution Item	Proxy Results					
		For	Against	Abstain	Valid Open Proxy's Discretion ***	Invalid/ Excluded/ Open unusable **	Total *
1 Ordinary	<b>Resolution 1</b> Approval of Norbio Acquisition	49,753,797	2,676	0	983,019	0	50,739,492
2 Ordinary	<b>Resolution 2</b> Approval of Cardio Acquisition	49,755,297	1,176	0	983,019	0	50,739,492

\* There were no invalid votes.

\*\* There were no votes in the “votes excluded / no instruction” column in the table above where the nominee registered shareholder had not received instructions from the beneficial shareholder. The votes in this column are votes unable to be cast due to voting restrictions as outlined in the Notice of Meeting.

\*\*\* Of the ‘undirected votes’, all votes for Resolutions 1 and 2 (inclusive) were cast with the Chair as proxy, which as outlined in the Notice of Meeting would be voted FOR all resolutions.

B. The following resolutions were passed without resort to a poll at the EGM of NOX on 6 November 2017.

Resolution 1:

Approval of Norbio Acquisition.

The motion was *carried* as an ordinary resolution on a show of hands.

Resolution 2:

Approval of Cardio Acquisition.

The motion was *carried* as an ordinary resolution on a show of hands.

Yours Sincerely



**David Franks**  
Company Secretary  
Noxopharm Limited

For further information, please contact:

David Franks  
P: +61 2 9299 9690  
E: dfranks@fa.com.au

### ***ABOUT NOXOPHARM LIMITED***

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development. The Company also has initiated a pipeline of non-oncology drugs.